Volume 60, Issue 6, Pages (December 2011)

Slides:



Advertisements
Similar presentations
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Advertisements

Volume 68, Issue 6, Pages (December 2015)
Volume 56, Issue 5, Pages (November 2009)
Volume 62, Issue 3, Pages (September 2012)
Volume 72, Issue 1, Pages (July 2017)
Volume 155, Issue 3, Pages (March 1996)
Volume 59, Issue 2, Pages (February 2011)
The PSA Era is not Over for Prostate Cancer
Volume 68, Issue 6, Pages (December 2015)
Volume 52, Issue 1, Pages (July 2007)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Testosterone Therapy in Men With Prostate Cancer
Volume 74, Issue 4, Pages (October 2018)
Volume 53, Issue 4, Pages (April 2008)
Volume 70, Issue 6, Pages (December 2016)
Volume 52, Issue 1, Pages (July 2007)
Volume 72, Issue 1, Pages (July 2017)
Prostate Cancer: Highlights from 2006
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Volume 69, Issue 4, Pages (April 2016)
Volume 69, Issue 1, Pages (January 2016)
Volume 51, Issue 4, Pages (April 2007)
Volume 70, Issue 4, Pages (October 2016)
Volume 62, Issue 1, Pages (July 2012)
Volume 52, Issue 4, Pages (October 2007)
Volume 68, Issue 4, Pages (October 2015)
Volume 68, Issue 1, Pages (July 2015)
Volume 59, Issue 2, Pages (February 2011)
Volume 67, Issue 2, Pages (February 2015)
Volume 68, Issue 5, Pages (November 2015)
Volume 53, Issue 4, Pages (April 2008)
Volume 70, Issue 5, Pages (November 2016)
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 68, Issue 3, Pages (September 2015)
Volume 67, Issue 3, Pages (March 2015)
Volume 67, Issue 6, Pages (June 2015)
Volume 71, Issue 5, Pages (May 2017)
Volume 73, Issue 4, Pages (April 2018)
Volume 185, Issue 2, Pages (February 2011)
Luis Martínez-Piñeiro  European Urology Supplements 
The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Validation of Preoperative Nomograms Predicting Lymph Node Involvement in Prostate Cancer: A Bi-institutional Study  Alexander I. Hinev, Vesselin I. Hadjiev,
Volume 74, Issue 2, Pages (August 2018)
Volume 53, Issue 4, Pages (April 2008)
Volume 58, Issue 1, Pages 1-7 (July 2010)
Volume 63, Issue 3, Pages (March 2013)
Volume 65, Issue 6, Pages (June 2014)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Physical Activity and Survival After Prostate Cancer
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Volume 58, Issue 1, Pages (July 2010)
Volume 50, Issue 5, Pages (November 2006)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
Volume 52, Issue 6, Pages (December 2007)
Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.
Prostate Cancer Nomograms: An Update
Volume 71, Issue 5, Pages (May 2017)
Testicular Cancer Variations in Time and Space in Europe
Volume 49, Issue 4, Pages (April 2006)
Volume 72, Issue 1, Pages (July 2017)
Volume 74, Issue 6, Pages (December 2018)
Axel Heidenreich  European Urology Supplements 
Volume 53, Issue 5, Pages (May 2008)
Volume 54, Issue 1, Pages (July 2008)
Volume 53, Issue 2, Pages (February 2008)
Fernando P. Secin, Fernando J. Bianco, Nicholas T
Axel Heidenreich  European Urology Supplements 
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 60, Issue 6, Pages 1226-1234 (December 2011) SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy  Etienne Audet-Walsh, Judith Bellemare, Geneviève Nadeau, Louis Lacombe, Yves Fradet, Vincent Fradet, Shu-Pin Huang, Bo-Ying Bao, Pierre Douville, Hugo Girard, Chantal Guillemette, Eric Lévesque  European Urology  Volume 60, Issue 6, Pages 1226-1234 (December 2011) DOI: 10.1016/j.eururo.2011.06.020 Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 1 Risk of recurrence associated with known (A) clinical and pathologic prognostic variables and (B) germ-line variations in SRD5A genes for white men with localised prostate cancer (n=526). Boxes represent hazard ratios (HRs) and their 95% confidence intervals in multivariate analyses as described in Table 2. Prostate-specific antigen (PSA) categories are in nanograms per milliliter. Reference categories (HR: 1.00) for clinicopathologic characteristics are PSA at diagnosis ≤10 ng/ml, pathologic Gleason score ≤6, and pathologic stage ≤pT2c. Reference categories (HR: 1.00) for genotypes are individuals with a major allele (homozygous or heterozygous, as described in Table 2). Genetic linkage between haplotype-tagging single nucleotide polymorphisms tested for each SRD5A gene is represented in the triangles on the left in panel B. NS=nonsignificant. European Urology 2011 60, 1226-1234DOI: (10.1016/j.eururo.2011.06.020) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier curves of biochemical recurrence for (A) SRD5A1 and (B) SRD5A2 in cohort of localised cases of white men with prostate cancer (n=526). Log-rank (LR) p values are shown in each frame. European Urology 2011 60, 1226-1234DOI: (10.1016/j.eururo.2011.06.020) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 3 Protective effects of single nucleotide polymorphisms in SRD5A genes in whites (rs12470143 and rs518673; n=526) and Asians (rs12470143; n=320) with localised prostate cancer. Hazard ratios (HRs) and their 95% confidence intervals (CIs) in multivariate analyses are indicated under each biochemical recurrence (BCR)–free curve. The BCR rate for every group is also indicated below each frame (% BCR). European Urology 2011 60, 1226-1234DOI: (10.1016/j.eururo.2011.06.020) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 4 Haplotype-tagging single nucleotide polymorphisms in SRD5A genes associated with an increased risk of biochemical recurrence after radical prostatectomy in whites (n=526) and in Asians with localised prostate cancer (n=320). Boxes represent hazard ratios (HRs) and their 95% confidence intervals (CIs) in multivariate analyses for rs676033, rs4952197, rs2208532 and rs523349. Reference categories (HR: 1.00) for genotypes are individuals with a major allele (homozygous and heterozygous); in Asians, rs2208532 tags for rs523349. European Urology 2011 60, 1226-1234DOI: (10.1016/j.eururo.2011.06.020) Copyright © 2011 European Association of Urology Terms and Conditions